Hemostasis & Tissue Sealing Agents Market continues to grow with Ethicon LLC introducing SURGICEL powered absorbable hemostat that assists to combat disruptive bleeding on broad and oozing surfaces

 

Hemostatic treatment is a process that involves the removal of excess hemostatic fluid from the valves in your legs and/or the valves themselves. For those with hemostatic varicose veins, which is what many people experience with hemostatic therapy, a hemostatic varicose vein dresser may help to reduce the swelling and pressure on the legs.

Increasing incidence of injuries caused by sports activities and road accidents is expected to drive growth of the global hemostasis & tissue sealing agents market. According to the Centers for Disease Control and Prevention (CDC), around 8.6 million sports and recreation-associated injuries are reported each year in the U.S. According to the same source, the injury rates are higher among males, with children aged 5-14 years. Moreover, according to the World Health Organization (WHO), every year around 20 and 50 million people suffer from non-fatal injuries with many people suffering from a disability. Such a high incidence of these injuries has increased the demand for tissue sealing agents. Hemostasis and tissue sealing agents offer several advantages such as reduced operating time, minimal incision, and reduced post-operative infection risks, and more. Hence, such factors are expected to drive growth of the global hemostasis & tissue sealing agents market. Furthermore, increasing number of surgeries and the advent of ready-to-use products is expected to propel growth of the global hemostasis & tissue sealing agents market in the near future.

Stringent regulatory scenario related to product approval coupled with high cost of tissue sealing agents is expected to hamper growth of the global hemostasis & tissue sealing agents market in the near future. Among regions, North America is expected to witness significant growth in the global hemostasis & tissue sealing agents market. This is owing to rising prevalence of cardiovascular diseases and diabetes in the region. According to the American Diabetes Association, in 2018, around 34.2 million people in the U.S. had diabetes. Furthermore, Asia Pacific is expected to register a robust growth rate, owing to increased medical tourism and surgical procedures across emerging economies such as China and India.

Key players involved in the global hemostasis & tissue sealing agents market are Johnson & Johnson, Bioster and Nycomed, CryoLife, Baxter, Entegrion, B. Braun, Cohera Medical, Advanced Medical Solutions Group, and Omrix Biopharmaceuticals.

For instance, in January 2018, Ethicon LLC, a subsidiary of Johnson & Johnson, launched SURGICEL powered absorbable hemostat that assists to combat disruptive bleeding on broad and oozing surfaces.